CURTISS-WRIGHT CORP

Learn how Curtiss‑Wright Corp’s 2026 AGM will shape its future: hybrid voting, director re‑appointments, a 10 % capital‑raising resolution and executive pay details.

Explore Curtiss‑Wright’s 2026 AGM: key governance, financial insights, and growth plans in aerospace, green aviation, and tech innovation.

Mayne Pharma confirms FDA approval for IMVEXXY® after a 9‑million‑woman safety study, boosting confidence for menopausal women and strengthening its US market position.

Investors learn how Curtiss‑Wright’s CFO exit and interim appointment may reshape its debt strategy, audit integrity, and defense‑contract competitiveness.

Discover how Curtiss‑Wright Corp’s shift from micro‑finance to secured lending boosts margins, cuts risk, and projects mid‑teens ROE for investors.